EUVIMED · CrossrefZeitschrift
The Lancet Neurology
ISSN 1474-4422 · Elsevier BV
Neueste Artikel
Safety, tolerability, and efficacy of bepranemab in people living with prodromal-to-mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2 trial
Safety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial
Neuroimaging in the era of biologically defined Alzheimer's disease and disease-modifying therapy
Cholinesterase inhibitors in people with dementia with Lewy bodies and cardiac conduction abnormalities
Intensive blood pressure lowering after spontaneous intracerebral haemorrhage for secondary stroke prevention (RECAP-ICH): a systematic review and individual participant data meta-analysis
Epstein–Barr virus and multiple sclerosis: from associations to mechanisms to potential therapies
Parkinson's disease genetics across diverse ancestries: an observational genetic study of causal and risk variants with translational implications
Safety and efficacy of staged, bilateral magnetic resonance-guided focused ultrasound pallidothalamic tractotomy for motor complications of Parkinson's disease: a prospective, multicentre, single-arm trial
Safety and efficacy of decompressive craniectomy versus standard craniotomy for large acute epidural haematoma with tentorial herniation in China (PREDICT-AEDH): a nationwide, multicentre, open-label, parallel-group, randomised controlled trial
Safety and efficacy of levacetylleucine in ataxia-telangiectasia: a phase 3, randomised, double-blind, placebo-controlled crossover trial
Clinical presentations and pathophysiological mechanisms of dystroglycanopathy: advancing therapeutic strategies
New evidence on the clinical, genetic, and biochemical bases of GBA1-Parkinson's disease: prospects for treatment
Diagnosis and pathogenesis of dystonia: clinical heterogeneity, shared mechanisms, and neurodevelopmental origins
Safety and efficacy of the anti-α-synuclein monoclonal antibody amlenetug for the treatment of patients with multiple system atrophy (AMULET): a phase 2, randomised, double-blind, multicentre trial
Safety, tolerability, and efficacy of acetazolamide in idiopathic normal pressure hydrocephalus (DRAIN) in Sweden: a randomised, double-blind, placebo-controlled, phase 2 trial
Endovascular treatment for medium or distal vessel occlusion stroke (DISTAL): 12-month outcomes of a multicentre, open-label, randomised trial
Cognitive resilience in ageing: determinants and interventions
Optimising blood pressure control after stroke: established wisdom and new frontiers
Safety and efficacy of individualised exercise and NAD+ precursor supplementation in patients with Friedreich's ataxia in the USA: a single-centre, 2 × 2 factorial, randomised controlled trial
Biomarkers for advancing diagnosis and prognosis in stroke
Traumatic brain injury in China: an update on epidemiology, care pathways, and clinical research
Stroke in China: advances in prevention and management on the path to a healthy China
Integration of plasma eMTBR-tau243 and p-tau217 in the diagnosis and stratification of Alzheimer's disease: a prospective cohort study
Advances in migraine prevention
A path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA
Safety and efficacy of eslicarbazepine acetate for seizure prevention in patients with stroke at high risk of developing post-stroke epilepsy: a proof-of-concept, phase 2a, randomised, double-blind, placebo-controlled antiepileptogenesis trial
Safety and efficacy of intensive task-specific training in people with recent spinal cord injury: a phase 3, pragmatic, randomised, assessor-blinded, superiority trial
Safety and efficacy of fordadistrogene movaparvovec in ambulatory participants with Duchenne muscular dystrophy (CIFFREO): a phase 3, double-blind, randomised, placebo-controlled study
The optimisation of migraine prevention: an urgent need
EUVIMED